# Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

> **NCT03974243** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Non-hodgkin's Lymphoma

## Interventions

- **DRUG:** Chiauranib
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT03974243
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-11
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03974243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03974243, "Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03974243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*